View in EDS

The β-catenin-LINC00183-miR-371b-5p-Smad2/LEF1 axis promotes adult T-cell lymphoblastic lymphoma progression and chemoresistance.

Saved in:
Bibliographic Details
Title: The β-catenin-LINC00183-miR-371b-5p-Smad2/LEF1 axis promotes adult T-cell lymphoblastic lymphoma progression and chemoresistance.
Authors: Huang WJ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China., Guo SB; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Shi H; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China., Li XL; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China., Zhu Y; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.; Anhui Public Health Clinical Center, Hefei, China., Li M; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China., Song LY; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China., Yu RM; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China., Cai QQ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Tian XP; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. tianxp@sysucc.org.cn.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. tianxp@sysucc.org.cn.
Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Apr 28; Vol. 42 (1), pp. 105. Date of Electronic Publication: 2023 Apr 28.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37106379
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The β-catenin-LINC00183-miR-371b-5p-Smad2/LEF1 axis promotes adult T-cell lymphoblastic lymphoma progression and chemoresistance.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Huang+WJ%22">Huang WJ</searchLink>; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Guo+SB%22">Guo SB</searchLink>; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Shi+H%22">Shi H</searchLink>; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Li+XL%22">Li XL</searchLink>; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhu+Y%22">Zhu Y</searchLink>; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.; Anhui Public Health Clinical Center, Hefei, China.<br /><searchLink fieldCode="AU" term="%22Li+M%22">Li M</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Song+LY%22">Song LY</searchLink>; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Yu+RM%22">Yu RM</searchLink>; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.; Biotechnological Institute of Chinese Materia Medical, Jinan University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Cai+QQ%22">Cai QQ</searchLink>; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Tian+XP%22">Tian XP</searchLink>; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. tianxp@sysucc.org.cn.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. tianxp@sysucc.org.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228308647%22">Journal of experimental & clinical cancer research : CR</searchLink> [J Exp Clin Cancer Res] 2023 Apr 28; Vol. 42 (1), pp. 105. <i>Date of Electronic Publication: </i>2023 Apr 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8308647 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1756-9966 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203929078%22">03929078 </searchLink><i>NLM ISO Abbreviation: </i>J Exp Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37106379
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s13046-023-02670-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 105
    Titles:
      – TitleFull: The β-catenin-LINC00183-miR-371b-5p-Smad2/LEF1 axis promotes adult T-cell lymphoblastic lymphoma progression and chemoresistance.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Huang WJ
      – PersonEntity:
          Name:
            NameFull: Guo SB
      – PersonEntity:
          Name:
            NameFull: Shi H
      – PersonEntity:
          Name:
            NameFull: Li XL
      – PersonEntity:
          Name:
            NameFull: Zhu Y
      – PersonEntity:
          Name:
            NameFull: Li M
      – PersonEntity:
          Name:
            NameFull: Song LY
      – PersonEntity:
          Name:
            NameFull: Yu RM
      – PersonEntity:
          Name:
            NameFull: Cai QQ
      – PersonEntity:
          Name:
            NameFull: Tian XP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 04
              Text: 2023 Apr 28
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1756-9966
          Numbering:
            – Type: volume
              Value: 42
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of experimental & clinical cancer research : CR
              Type: main
ResultId 1